Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Pediatric Obesity
Dietary Fructose: a Metabolic Switch in Pediatric Obesity-related Disease.
The increase in childhood obesity is a multifactorial phenomenon influenced by dietary patterns, commercial factors, and social determinants; it has long-term consequences for both individual health and society as a whole.
- Trial name
- EO2022 (NCT06365567)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
Fatty Liver, Nonalcoholic
The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver
L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is involved in transporting fatty acids across the mitochondrial membrane, it could be an important component in treating a fatty liver disease.
- Trial name
- NCT03319199
- Testing
- "SLIM WATER"
- Where
- Israel
- Volunteers
- 22 people
- Sponsor
- Rawi Hazzan
Fatty Liver, Nonalcoholic Steatohepatitis
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
This study will evaluate the effectiveness of pioglitazone, a new diabetes medicine, on decreasing insulin resistance and improving liver disease in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT00013598
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non-Alcoholic Fatty Liver Disease
FCI Effectiveness in NAFLD Stratification
The goal of this pilot study is exploring whether field-cycling imaging may be able to detect characteristics of liver disease in patients with different degree of non-alcoholic fatty liver disease (NAFLD) that could be important…
- Trial name
- FIELDS (NCT05827432)
- Testing
- Field-cycling imaging (FCI)
- Where
- United Kingdom
- Sponsor
- NHS Grampian
Non-alcoholic Fatty Liver Disease
Hepatic Inflammation and Physical Performance in Patients With NASH
The aim of the study is to examine the influence of hepatic inflammation or damage on physical performance (maximal oxygen uptake, VO2max) depending on the histologic state of the liver.
- Trial name
- HELP (NCT02526732)
- Testing
- individual training program
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Priv.-Doz. Dr. J. Schattenberg
NAFLD
The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is a disease of alarmingly increasing prevalence, linked to metabolic, cardiovascular and malignant morbidity and without any officially approved treatment.
- Trial name
- NAFTx (NCT04465032)
- Testing
- Gut microbiome transplantation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Non Alcoholic Fatty Liver Disease
Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients
The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD patients and to assess the influence of Px-104 on hepatic fat.
- Trial name
- NCT01999101
- Testing
- Px-104
- Where
- Austria
- Volunteers
- 12 people
- Sponsor
- Phenex Pharmaceuticals AG
NAFLD, NASH
The European NAFLD Registry
The European NAFLD Registry is a prospectively recruited, observational study supporting the study of the clinical phenotype, natural history, disease outcomes and pathophysiology of Non-Alcoholic Fatty Liver Disease and…
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT04442334
- Where
- 37 sites in Belgium, Finland and 10 more
- Volunteers
- 10,000 people
- Sponsor
- Newcastle University
NASH - Nonalcoholic Steatohepatitis, Insulin Sensitivity
Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH
Non-alcoholic steato-hepatitis (NASH) affects up to 3% of the population and leads to liver cirrhosis, hepatocellular carcinoma (HCC) and death. The only known treatment is weight loss and exercise.
- Trial name
- ELVIS (NCT03490370)
- Testing
- Electro-muscular stimulation using NeuroTrac MyoPlus 2/4
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- NHS Tayside
Chronic Liver Disease, Liver Fibrosis
Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch
This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with…
- Conditions
- Chronic Liver Disease, Liver Fibrosis, Liver Steatoses
- Trial name
- OGIG-01-22-LF (NCT05224037)
- Testing
- iLivTouch
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Federal State Budgetary Scientific Institution
PreDiabetes, NAFLD
Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)
Tree nuts - such as almonds - contribute to beneficial effects of the Mediterranean diet on risk for cardiovascular events, type 2 diabetes, dyslipidemia, hypertension, inflammation and non-alcoholic fatty liver disease.
- Trial name
- AGAMEMNON (NCT06413069)
- Testing
- Raw whole almonds
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant
The primary objective of this study is to determine the effect of hepatic impairment on the pharmacokinetics (PK) of miricorilant following a single oral dose by comparing participants with normal hepatic function with…
- Trial name
- NCT05553470
- Testing
- Miricorilant
- Where
- 3 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Non-Alcoholic Fatty Liver Disease
Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients
This study was designed to assess the relation between serum ferritin and hepatic fibrosis in patients with NAFLD. It included 83 patients with NAFLD with or without hepatic fibrosis, in addition to 30 healthy subjects included…
- Trial name
- NCT03250572
- Testing
- serum ferritin
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Non-alcoholic Fatty Liver Disease
Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease
In China, with the improvement of living standards, there is a significant increase in the rate of prevalence of type 2 diabetes and hyperlipidemia, associated with Non-alcoholic fatty liver disease（NAFLD） which has gradually…
- Trial name
- NAFLD (NCT03648086)
- Testing
- intestinal microbiota transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhongshan Hospital Xiamen University
Non-Alcoholic Steatohepatitis
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children
The purpose of this study is to document how often specific genotypes known to be associated with adult-onset NASH (Non-Alcoholic Steatohepatitis) occur in a pediatric cohort and investigate whether these genotypes are associated…
- Trial name
- NASH (NCT00677183)
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Cirrhosis, End Stage Liver Disease
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Acute kidney injury (AKI), or worsening kidney function, is a common complication after liver transplantation (20-90% in published studies).
- Conditions
- Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications
- Trial name
- MHALT (NCT03534141)
- Testing
- Esophageal cooling/warming device, Mild hypothermia, Normothermia
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of California, San Francisco
Non-Alcoholic Fatty Liver Disease, Obesity
Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study
Non alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function tests in the U.S. (Browning, et al., 2004), ranging from steatosis to end-stage liver disease.
- Trial name
- NCT03339245
- Testing
- Fructose Solution (75 Grams), Glucose Solution (75 grams)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 2 study to determine if JKB-122 compared with placebo resolves NASH on liver biopsy and improves fibrosis
- Trial name
- NCT04255069
- Testing
- Dose 1 JKB-122, Dose 2 JKB-122
- Volunteers
- 300 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Obesity, NAFLD
Bariatric Endoscopy and NAFLD
Find out how bariatric endocopy will influence clinical course of non alcoholic fatty liver disease.
- Conditions
- Obesity, NAFLD, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT04669470
- Testing
- bariatric endoscopy, mainly intragastric baloons, plication of stomach too
- Where
- Czechia
- Volunteers
- 100 people
- Sponsor
- University of Ostrava
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.